Background.
Vancomycin is challenging to dose due to a narrow therapeutic index. Inadequate dosing undertreats dangerous infections, while high doses can cause Acute Kidney Injury (AKI). Standard pediatric vancomycin dosing (40-60 mg/kg/day) often produces inadequate troughs. Our institution began permitting a higher initial vancomycin dose: 80 mg/kg/day for children 1 month to 12 years old, and 60 mg/kg/day for children ≥ 13 years old. This study aims to determine whether higher dosing has increased the rate of therapeutic troughs or the rate of AKI.
Methods. A retrospective review was conducted of patients < 18 years of age who were admitted to our institution and received vancomycin. 842 unique courses of vancomycin were identified and age, sex, race, vancomycin dosing, trough results, and creatinine data were abstracted. 450 records were excluded based on criteria of age < 1 month, pre-existing renal failure, or no measured troughs. 392 unique vancomycin courses for 340 unique patients were analyzed. Therapeutic troughs were defined as 10-20 µg/mL. Statistical analysis was performed using Chi-square test, Fisher's exact test, and unpaired t-test.
Results. Younger patients with higher vancomycin dosing attained an initial therapeutic trough in 41.1% vs. 32.7%.
Conclusion. A higher initial vancomycin dose trended toward an improved rate of therapeutic troughs in children 1 month to 12 years old. There was no evidence of increase in the rate of AKI or supratherapeutic troughs. While vancomycin dosing remains challenging, a policy permitting higher initial dosing may more adequately treat dangerous infections without risking adverse effects. Further study of higher vancomycin dosing is warranted.
Disclosures. All authors: No reported disclosures. Background. Aerosolized or powdered forms of polymyxin have been used as prophylaxis for ventilator associated infections in adults. In 2015, Children's National Medical Center neonatal intensive care unit (NICU) protocol recommended that neonates <1,000 g receive polymyxin endotracheal tube suction catheter flushes with the goal to reduce acquired respiratory infection. The objective of this study was to describe the clinical characteristics and outcomes of patients who received polymyxin endotracheal tube flushes compared with those who received saline.
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Methods. A retrospective cohort study of infants weighing <1,000 g ventilated for >48 hours in the NICU, January 1, 2015-June 30, 2016 was performed. Data were collected from an internal NICU database, medication billing data, and through chart review of the electronic health record. Demographics, antibiotic treatment days, ventilator days, length of stay, mortality, and microbiologic culture data were compared between patients receiving polymyxin and saline using chi-squared for binary and t-test for continuous variables.
Results. Of the 71 patients included, 38 received polymyxin and 33 received saline. Mean gestational age at birth was 24.1 weeks (23.9 polymyxin vs. 24.2 saline, P = 0.06); median age on admission 4 days (3 vs 12, P = 0.019); median admission weight 700 g (640 vs. 800, P = 0.002); 52% were male (58% vs. 45% group). Median antibiotic days was 52 (77 vs. 41, P = 0.056), median ventilator days 39 (43.5 vs. 33, P = 0.06). Pathogenic bacteria was cultured in 38% of patients in whom at least one lower respiratory tract (LRT) culture was obtained (62.5% vs. 38.1% P = 0.24). Pathogenic bacteria resistant to at least one antibiotic class to which is normally susceptible was found in 10% (13% vs. 6%, P = 0.32). No differences were seen in mortality (16% vs. 15%, P = 0.94) or median length of stay (101 vs. 92, P = 0.41).
Conclusion. An NICU protocol recommending prophylactic polymyxin use for ELBW infants was implemented more frequently in younger and more premature neonates. Mortality and length of stay did not differ among babies who received polymyxin. Patients who received polymyxin did not grow a statistically significant higher proportion of pathogenic or resistant bacteria from LRT cultures compared with those receiving saline.
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